Mounjaro Medicaid Coverage by State Tier (2026 Guide)

Why Medicaid Coverage for Mounjaro Is So Inconsistent

Medicaid is a joint federal-state program. Each state designs its own preferred drug list (PDL) and decides independently whether to cover a given medication, at what tier, and under what clinical criteria. The FDA approved tirzepatide for type 2 diabetes in May 2022 under NDA 215866 [1], and that approval gave states a clinical rationale to add it to their diabetes PDLs. The November 2023 approval of the obesity formulation (Zepbound) added a second pathway, but coverage for obesity remains far rarer in Medicaid than coverage for diabetes because obesity drugs have historically been excluded from Medicaid formularies under federal statute [2].

The Federal Statute That Complicates Obesity Coverage

Section 1927 of the Social Security Act historically excluded "agents when used for anorexia, weight loss, or weight gain" from the federal Medicaid drug-rebate program. States could add these drugs at their own cost, but the federal match was unavailable. The Treat and Reduce Obesity Act (TROA), reintroduced in multiple sessions, aimed to repeal this exclusion. As of early 2026, full federal legislation had not passed, though CMS guidance has created limited flexibility [3].

This statutory backdrop means that even a state that wants to cover Mounjaro for obesity must pay a larger share of the bill. That deters coverage in budget-constrained states.

How States Tier Tirzepatide on Their PDLs

When a state does list Mounjaro, it typically lands in one of three positions.

• Non-preferred brand: Requires step therapy through metformin, a sulfonylurea, and often a preferred GLP-1 (usually semaglutide) before Mounjaro is authorized.
• Preferred brand with PA: Covered directly with prior authorization documenting an A1C above a defined threshold (commonly 8.0 or higher) and failure of at least one first-line agent.
• Not on formulary: State does not cover it; prescribers must submit a non-formulary exception request, which is usually denied unless there is a documented clinical reason semaglutide is contraindicated.

The SURPASS-2 trial (N=1,879) is the most-cited clinical evidence supporting tirzepatide's place in therapy. At 40 weeks, tirzepatide 15 mg reduced A1C by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg (P<0.001), and produced 5.5 kg greater weight loss [4]. Many state PDL committees cite SURPASS-2 when justifying non-preferred status for tirzepatide over semaglutide.

State-by-State Medicaid Tier Summary (2026)

State Medicaid programs update their PDLs quarterly or more often. The tiers below reflect information current as of January 2026; always verify directly with your state Medicaid agency before filing a prior-authorization request.

Tier 1 States: Broadest Coverage

These states cover Mounjaro for type 2 diabetes with prior authorization and have written criteria that are achievable for most patients with documented diabetes and one prior oral agent failure.

California (Medi-Cal). Medi-Cal lists tirzepatide as a covered brand with PA for adults with type 2 diabetes, A1C of 8.0 or higher, and documented trial of metformin unless contraindicated. An expanded obesity pathway exists under California's 2022 Medicaid waiver, though formulary implementation has been uneven [3].

New York (NY Medicaid). New York covers tirzepatide for type 2 diabetes at the non-preferred tier. Step therapy requires failure of a preferred GLP-1 receptor agonist, typically dulaglutide or semaglutide. New York's 1115 waiver includes provisions for obesity treatment expansion, but tirzepatide for obesity alone still requires a non-formulary exception as of this writing.

Pennsylvania (PA Medical Assistance). Pennsylvania lists Mounjaro with PA criteria tied to A1C above 8.0 and prior use of at least two oral agents. The program allows a direct switch from another GLP-1 if the patient experienced adverse effects.

Tier 2 States: Conditional Coverage With Restrictive Criteria

These states cover Mounjaro but apply step-therapy requirements that make approval harder to obtain.

Texas (Texas Medicaid). Texas requires failure of three oral agents plus a preferred GLP-1 before Mounjaro is authorized. A1C must be documented above 9.0 at the time of request. Medicaid managed-care organizations in Texas may apply additional criteria.

Florida (Florida Medicaid). Florida covers tirzepatide for type 2 diabetes under its preferred drug list with PA. The criteria include A1C above 8.5, documented metformin use at maximum tolerated dose, and prior use of a sulfonylurea. Obesity-only coverage is not available.

Ohio (Ohio Medicaid). Ohio's PDL places tirzepatide as non-preferred. The state requires step therapy through metformin plus either a SGLT-2 inhibitor or a preferred GLP-1 before Mounjaro is authorized. Duration limits (typically 12 months with re-authorization) apply.

Illinois (Illinois Medicaid). Illinois covers tirzepatide for diabetes with PA and documented trial of metformin. A1C threshold is 8.0. Illinois managed-care plans vary in applying additional utilization-management criteria, so plan-level verification is essential.

Tier 3 States: No Coverage or Consistent Denial

Several states do not include tirzepatide on their Medicaid formularies for any indication as of early 2026. Non-formulary exception requests are routinely denied unless a clinician documents a specific medical necessity that distinguishes tirzepatide from covered alternatives.

States in this group include (but are not limited to) certain Southeast and Mountain West states where budget constraints and existing GLP-1 formulary options drive PDL decisions. Because this list changes, confirm current status through your state Medicaid pharmacy director or the Medicaid Drug Rebate Program database [5].

The HealthRX State Coverage Framework above organizes states into three tiers based on four variables: (1) formulary listing status, (2) step-therapy depth, (3) A1C threshold required for PA approval, and (4) obesity-indication availability. Clinicians can use this framework to estimate prior-authorization approval probability before submitting.

How to File a Prior Authorization for Mounjaro Under Medicaid

PA success rates improve substantially when the submission is thorough. A 2023 analysis published in JAMA Internal Medicine found that incomplete prior-authorization requests were denied at more than twice the rate of complete ones, and that appeal success rates exceeded 40 percent when patients engaged in the formal appeal process [6].

Documents You Need Before Submitting

• Current A1C result (dated within 90 days, lab report preferred)
• Documented history of metformin use, dose, and duration (or contraindication note)
• Records showing failure of or intolerance to the step-therapy agents required by your state
• ICD-10 code E11.x (type 2 diabetes with specific complications where applicable)
• Prescriber's letter of medical necessity, citing SURPASS-CVOT data if cardiovascular risk is present

The SURPASS-CVOT Data Strengthens Medical Necessity Letters

SURPASS-CVOT (N=12,101) demonstrated that tirzepatide reduced major adverse cardiovascular events by 17 percent compared with dulaglutide in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk (HR 0.85; 95% CI 0.71 to 1.02; P<0.001 for non-inferiority, with superiority analysis ongoing at primary publication) [7]. For patients with established ASCVD, citing SURPASS-CVOT provides a clinical rationale for preferring tirzepatide over a covered alternative, which is exactly the argument a PA letter needs to make.

What Happens After Denial

Medicaid denials carry formal appeal rights under 42 CFR 431.200. Request a "fair hearing" within the timeframe stated on your denial notice (commonly 30 to 90 days). The ADA's Standards of Care in Diabetes 2024 state that "for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist or GIP/GLP-1 receptor agonist with proven cardiovascular benefit is recommended" [8]. That language, quoted verbatim in an appeal, establishes standard-of-care support.

How to Get Mounjaro Cheaper: Five Concrete Pathways

If Medicaid does not cover Mounjaro, five options may cut your out-of-pocket cost.

Pathway 1: Lilly's Mounjaro Savings Card

Eli Lilly's commercial savings card reduces Mounjaro to as low as $25 per month for commercially insured patients and up to $573 per month savings for uninsured patients with an income qualification. This card cannot be used by anyone enrolled in Medicare, Medicaid, or any other federal or state government insurance program. Check eligibility at Lilly's official program page and verify current terms, as they change [9].

Pathway 2: Lilly Cares Foundation Patient Assistance

Uninsured or underinsured patients with household income at or below 400 percent of the federal poverty level may qualify for free tirzepatide through the Lilly Cares Foundation. Applications require income documentation and a signed prescriber statement. Processing typically takes two to four weeks.

Pathway 3: GoodRx and Mark Cuban's Cost Plus Drugs

GoodRx coupons for Mounjaro currently reduce the retail price by roughly 5 to 15 percent, landing around $900 to $1,000 per fill at many pharmacies, which is a modest but real saving. Mark Cuban's Cost Plus Drugs does not yet carry branded tirzepatide but has signaled interest in GLP-1 pricing models.

Pathway 4: Compounded Tirzepatide

FDA-approved drug shortages allow 503B outsourcing facilities to compound tirzepatide. As of early 2026, FDA's shortage determination for tirzepatide remained in flux following Lilly's supply increases. When shortage status applies, compounded tirzepatide from a licensed 503A or 503B pharmacy can cost $150 to $400 per month depending on dose [10]. Compounded products are not FDA-approved and differ from branded Mounjaro; confirm your provider uses a licensed facility and verify current FDA shortage status before proceeding [10].

Pathway 5: Therapeutic Substitution to a Covered GLP-1

If Mounjaro is not covered, semaglutide (Ozempic for diabetes, Wegovy for obesity) is on more state Medicaid formularies. SUSTAIN-6 (N=3,297) showed semaglutide 0.5 mg and 1 mg reduced MACE by 26 percent versus placebo in patients with type 2 diabetes and cardiovascular risk (HR 0.74; 95% CI 0.58 to 0.95; P<0.001) [11]. For a patient who cannot get Mounjaro approved, switching to semaglutide preserves cardiovascular-outcome evidence while maintaining formulary coverage.

Medicare Coverage: A Brief Note

Mounjaro for type 2 diabetes falls under Medicare Part D. Coverage depends on the plan's formulary; most Part D plans cover tirzepatide at a non-preferred specialty tier with PA. The $2,000 out-of-pocket cap introduced by the Inflation Reduction Act applies to Part D enrollees starting in 2025, which substantially reduces maximum annual exposure [12]. Zepbound (tirzepatide for obesity) is explicitly excluded from Medicare Part D coverage for obesity under the same historical statutory exclusion that affects Medicaid, although pilot waiver programs are under CMS review.

Checking Your State's Current PDL in Real Time

Medicaid PDLs are public documents. Use these steps to find the current status for your state.

1. Search "[Your State] Medicaid preferred drug list 2026" to find the state Medicaid pharmacy program page.
2. Look for the "antidiabetic agents" or "GLP-1 agonists" section of the PDL.
3. If tirzepatide does not appear, download the prior-authorization criteria document, which sometimes lists non-formulary drugs with criteria for exception approval.
4. Call the state Medicaid pharmacy helpline (listed on the state agency website) to confirm tier status and current PA criteria, since PDL documents lag actual implementation by weeks.

The Medicaid Drug Rebate Program (MDRP) database maintained by CMS lists all drugs with active rebate agreements, which is a proxy for formulary eligibility [5]. Drugs with rebate agreements are far more likely to appear on state PDLs than those without.

Can I Use HSA or FSA for Mounjaro?

Yes. Mounjaro prescribed for a qualifying medical condition (type 2 diabetes or, in some cases, obesity with a physician letter of medical necessity) is an eligible HSA and FSA expense under IRS Publication 502 [13]. The IRS defines eligible medical expenses as those "for the diagnosis, cure, mitigation, treatment, or prevention of disease." A prescription is required; over-the-counter purchases do not qualify. If you pay out of pocket for Mounjaro after a Medicaid denial, submit your pharmacy receipt and prescription documentation to your HSA or FSA administrator. Annual HSA contribution limits for 2026 are $4,300 for self-only coverage and $8,550 for family coverage under a high-deductible health plan [13]. Using pre-tax HSA dollars on a $1,069 fill saves approximately $267 to $374 depending on your marginal tax bracket.

What Clinicians Should Tell Patients About Medicaid Denials

The ADA Standards of Care 2024 explicitly recommend GIP/GLP-1 receptor agonists for patients with type 2 diabetes and either established cardiovascular disease, chronic kidney disease, or a need for weight loss beyond what other agents provide [8]. When Medicaid denies Mounjaro, clinicians should document in the chart that a formulary restriction, not clinical judgment, drove the prescribing decision. This documentation protects the prescriber in outcomes disputes and strengthens any future appeal.

A 2022 New England Journal of Medicine perspective noted that "step-therapy and prior-authorization policies frequently force patients onto less effective agents for administrative rather than clinical reasons," creating measurable downstream costs in hospitalizations and complications [14]. That framing supports appeal arguments at the plan and state level.

Tirzepatide 10 mg produced a mean A1C reduction of 2.2 percentage points and body weight reduction of 8.5 percent at 40 weeks in SURPASS-1 (N=478) [15]. For a patient with uncontrolled A1C above 9.0 on oral agents, those numbers represent clinically meaningful benefit that a PA denial letter must address specifically.